viernes, 13 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Via News Knowledge File

Target Corporation

organization80% conf.·synced Aug 13, 2026

Retail corporation

48
sourced metrics
387
relationships
20
stated objectives
2
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Daily Change
1.3percent
Nov 28, 2026source
Price 52 Week High
154.00USD
Aug 12, 2026reference only
Stock Price
154.00USD
Aug 12, 2026reference only
Price 52 Week Low
83.68USD
Aug 12, 2026reference only
Stock Return Ytd
53.2%
Aug 12, 2026reference only
Price To Earnings
17ratio
May 27, 2026source
Eps
+7.8percent_yoy
May 26, 2026source
Sga Rate
21.9percent
May 20, 2026source
Net Income
781USD
May 20, 2026source
Operating Income
1.1USD
May 20, 2026source
Operating Margin
4.5percent
May 20, 2026source
Comparable Store Sales Growth
4.7percent
May 20, 2026source
Operating Margin Prior Year Adjusted
3.7percent
May 20, 2026source
Eps Guidance High
8.50USD
May 20, 2026source
Margin
29.0percent
May 20, 2026source
New Stores Opened
7stores
May 20, 2026source
Eps Guidance Low
7.50USD
May 20, 2026source
Non Merchandise Sales Growth
24.6percent
May 20, 2026source

Stated objectives

Regain market share through private label brands and key discretionary categories

source
stated

Turnaround from declining in-store traffic and market share losses

source
by 2027-01-01 00:00:00stated

Achieve quarterly revenue of $24.26 billion

source
target: 24.26 billion USD stated

Achieve full year revenue of $106.78 billion

source
target: 106.78 billion USD stated

Source 100% of electricity from renewable sources

source
target: 100% by 2030-01-01 00:00:00stated

Drive more than $15 billion in sales growth through enhanced consumer experience and supply chain improvements

source
target: $15 billion by 2030-01-01 00:00:00stated

Invest more than $7 billion over three years including remodeling 1,000+ stores

source
target: $7 billion by 2020-12-31 00:00:00stated

Increase capital expenditure to support store remodels, larger-format locations, expanded fulfillment and major floor-pad upgrades

source
target: 5 billion USD stated

Full-year adjusted EPS outlook

source
target: 7.00-8.00 USD stated

Next fiscal year sales growth

source
target: 2.2% stated

Relationship graph · 387 connections

Competes with
108
Covered by
51
Supplies to
43
Employs
37
Developed by
35
headquartered in
18
Customer of
16
Owns
16

Via News coverage

Vicepresidente de Target demanda tras revocación de Global Entry por protesta contra ICE
January 31, 2026
Le revocan Global Entry a directora de Target tras protesta contra ICE que desata debate sobre privacidad biométrica
January 31, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com